We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Argent Biopharma Limited | RGT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 29/11/2024 08:45 by tomboyb delisting - |
Posted at 22/8/2024 13:15 by pierre oreilly Well I did own them briefly - sold them for 75 quid in total once I noticed them yesterday in my account. Afaics, they were the remnants of several thousand quid invested in mxc a couple of years ago, and now called Argent. (Nothing at all to do with the old RGT ticker which has just been recycled). Effectively bust due to the stupid government not authorising cannabis general use in the NHS. |
Posted at 21/8/2024 22:16 by dr biotech You don’t own them. Another company floated and used the RGT ticker… |
Posted at 10/4/2024 14:22 by blackhorse23 Money moving to APH [alliance pharma] , dividend announcement in 7 days |
Posted at 03/3/2016 08:20 by stenick For anyone interest, from Rgt accounts.Revenues from sales of ColostrininTM for the year to 31 December 2014 were £17,000 (2012 - £52,000). Administrative costs have come down from £179,000 last year to £95,000 in 2014. Overheads have again been kept to a minimum. It should also be noted that within this figure there are non-cash items of £80,000 compared with £155,000 in 2013. These charges represent depreciation of the filtration rig (£27,000), the amortisation of patents (£44,000) and the amortisation of goodwill (£9,000). As a result of these factors the loss for the period after tax amounted to £100,000 (2013 - £171,000). On the 17th May 2012 the Company drew down the last £40,000 of the £240,000 loan facility available from Alexander David Investments PLC. With interest this has now accrued to a debt of £322,000 as at 31 December 2014 and interest continues to accrue. Technically this convertible loan could now be called upon after 14th February 2014. As previously stated this loan was taken over by Tiziana Life Sciences Plc after their acquisition of Alexander David Investments Plc (“ADI”). Discussions with Tiziana management have clarified that they do not intend to call in this loan but would convert this loan to RGTL shares at an appropriate time. Sales are down from last year mainly as a result of an order not being placed by our US distributor during 2014, although an order was placed in early 2015. We are working with a new licensee in India to secure regulatory approval to distribute the product direct to consumers there. The application has been with the regulatory agency for some months and a decision is expected soon. Our USA licensee Metagenics introduced a Colostrinin combination product (CerivaTM) via the 'professional' channel in summer 2014. Active ingredient for this launch stock was the main source of RGTL revenue in 2013. Detailed information is unavailable from Metagenics to ascertain how well the product is being received in the marketplace but the fact that they have recently suggested that no more material will be required during the remainder of 2015 or during the early part of 2016 suggests that the product is not selling as well as was hoped. Having obtained regulatory approval to do so, Tagerr our distributor in Poland have now switched from distributing product made by Metagenics to tablets supplied by RGTL.These are being well received but obviously sales here are on a modest scale. Cost saving initiatives continue. The Company runs from a virtual office. Both Directors and consultants remain unpaid (since December 2012) and will continue to defer their remuneration/fees until there is funding/finance available. The Directors continue to explore various ways of financing and developing the company with its advisers and contacts in order to secure a viable future for the Company in the best interest of shareholders. This includes the outright sale of the Company to a buyer that has the resources to fully exploit the sales potential of Colostrinin. So far a serious potential buyer has not been identified. |
Posted at 17/3/2015 18:32 by impala391 Time has stood still for Rgt. |
Posted at 10/12/2014 19:14 by doorway so whats going on here then are rgt still alive,and when this delisted did anyone get their new certs as mine was in a nominee account |
Posted at 25/8/2011 09:51 by share_shark I have spent countless hours, since RGT became Newco, spreading the gospel around the USA and Poland(where I have contacts).Life is so very funny isnt it?. |
Posted at 15/7/2011 09:10 by the_doctor I'll repost this:A quick report from the RGT update meeting. 8 shareholders, plus 2 from the company. Tim did most of the talking, as expected. He had clear visions and put them across well. There have been issues, but they're doing what they can to get around them. I think we're in as good a pair of hands as we could hope with Tim really. He's realistic about the challenges and is focused on the right areas. Norman answered the financial questions without problem and again, appears realistic. In short, 2011 has gone well. I got the impression that orders so far already match those in 2010 (that wasnt said specifically) and more are anticipated. They havent used up the first £150k portion of the loan yet Cash burn rate of £20-25k per month. On an approx 60% margin, if they've so far got £100k from 2011 trading... I forget how much of the filtration unit/other expenses came out of the loan? If £35k, then for operations, there'd be £115k from the loan So, £225k in this year would mean they'd need to draw on the second part of the loan in Oct 2011. From then, they'll have about 5 months worth of cash. So, we have a window until approx end March 2012 But this will be extended with any further orders. Which in turn, will buy more time for more orders to come in. It looks tight to me, so orders over H2 2011 and H1 2012 are ESSENTIAL They do have a lot of things bubbling away that should lift revenue AND importantly, also margins. Producing their own RGT tablets increases the price RGT gets by about 50%. That would translate into a nice lift in cash flows from ex-US sales. Add to that, input from the recent/new distribution agreements signed... My overall view is that if they can get to 2013, then they're home and dry, as more deals kick in and the margins improve. The critical thing IMO is getting enough cash in to cover the 5-10 months running from end of the loans to sustainability... That will require £100-250k Or, orders of about £170-265k Roughly translated, they have approaching a year to bring in as many orders as they did in the last 6 months, or the same as the whole of 2010. That'll be facilitated by margin improvement and the launch of new formulations, but really depends on how long current stocks last before re-orders come in.... that's a bit of an unknown! Speed is of the essence. There isnt much scope for cost cutting, but I'd hope they'd cut back even further if they really had to, such as delaying/cutting down staff pay for a spell, putting them as creditors for what was owed until sustainable? |
Posted at 31/1/2011 23:56 by stav5001 I apologise as I wanted to post sooner, but a lot was discussed and it was hard to post it all on here. It was nice to meet ASMO and his friend. Asmo has already given good general overview of events, and I do not want to bore you all by revisiting the same points. I could have asked hundreds of barbed questions at the EGM, as I know what many here have been posting, and I understand the strength of feeling, but in the end, I decided against most of them, as we were effectively presented with a "coup de etat," we had no real option but to vote YES. For me there is no point dwelling on the negative, dark side. I prefer the light as it will always pierce the darkness. David Scott's presentation was corporate, slick and well presented, I expected no less, and he did not disappoint. If I was in his shoes, I would have probably done the same, and I actually said so later, in fact I liked him. However, my real focus was really on Newco. Tim Shilton, gave a calm, concise and clear presentation, regarding Newco, it is clear from the presentation that Newcos prime objective is to concentrate its energies on generating cashflow from the existing accounts, and work with the other parties that have shown an interest in opening new accounts. All other money draining ventures will be put on hold, (which clearly makes sense). Tim also said that the last agreement with LG was like a bolt out of the blue, as it was sent out a year ago, and came back signed, a year later without a single change! Reduced Overheads, according to Percy £300,000 less p.a. Wages bill now reduced to £50K All debts settled (including filtration unit) Retention of Patents 3 year Short-term finance (£240,000) secured @ 10% per Annum. Trading losses carried forward except a small amount that was utilised for the directors exit package. Increase the revenue to Newco Regen, through use of tablet form. Tim also assured me that they will retain the same website (but modified); there will be regular trading updates; Email contact with shareholders; clarification announcement if required, 6 monthly reports , an AGM and other adhoc meetings. When I said that it was easy with today's technology, or even using youtube to buy a webcam and give an update, Tim said that he was quite interested in technology, so did not rule this out. I have said "no looking back", but I did feel compelled to ask some questions for everyone. Like why, with expected news of break even for RGT, the recent new overseas contracts, and many investors recently buying at between 3.25P to 3.75P ( including me), that a home could not have been found for 12 million shares, at a higher price, perhaps 1P-2P at least. I also asked WHO.... bought the shares at that price. David Scot simply replied that the recent placing reflected the major placing at 0.5P. Percy Lomax implied that they had exhausted all sources of potential investors, and that the 12M RGT shares were placed with "an investor" who has supported RGT to the tune of £700,000 in total (that equates to a lot of shares at last years prices)? He also said that he wished, I had picked up the telephone and called earlier as he would have been more than happy to sell them to me, or any other RGT investors. I also made it clear that I found it very strange that I (a small PI and newcomer), owned almost as many shares as all RGT the directors combined, and indeed would have held more, if the news had not broken when it did. It was then that Percy said that his losses totalled £750,000. The Directors are not getting, or claiming back-pay for the years on half-salary, Percy said. The cash and share-options etc. are for contract termination. Clearly, if the company had ceased they would have received £0. The 5 year warrants at 0.01p are being issued as a tax mechanism, and are tied to the amount that they (the Directors) are owed. To put it simply they are owed £378,562.50 in total, less £80,000 which is being paid in cash following the demerger. So they will still be owed £298,562.50. Now if you divide this by the placing price of 0.5P, you get 597,125,000 shares. My understanding is that this is how many share options they will have, but they were issued at a nominal 0.01P to save tax instead. I tackled, them on this point, David Scott said he was very happy that I had raised this point, but it took a while for the NOMAD to put the meat on the bones. I brought the whole 0.01 options issue up, when I questioned just how fast the new ADS company could grow, when it would have to constantly overcome, this overhang / dilution which would be added to the existing 300,000,000 new ReGen ordinary shares, whenever the price looked like rising. David Scott assured me that" Everyone understood the position " and that there would be no wholesale selling, thus destablising their efforts. I also added that their holding of 29.9% of the new ADS Company, meant that they only needed an additional 0.1% to launch a takeover, if the new company was doing well. All in all, this all bodes well for ADS, these guys have played a blinder and pretty much covered all their bases, and I said so. I told David Scott that if I was negotiating for us, I would have at least held out for the £240,000 as a payment to Newco, not a loan. I also questioned the 10% pa, interest payments, not generous, in fact similar to what prospecting mining companies on AIM have to pay. Let's face reality, at the end of the day RGT was in a position of weakness, and everyone wanted their share. We now have two bites of the cherry. The New investment company clearly has some very intelligent professional backers, who do not want to see it fail, they have achieved their first goal, but most importantly for most of us here, is that Tim Shilton, seems quietly confident, and is still very positive about our new delisted companies future, with it's new low cost, efficient format, and global aspirations, HE (who knows most) believes we can fly, so why should I allow negative thoughts to stop the flight of a PHOENIX! We do not have a great deal to lose from where we are right now, but we do have everything to gain. Let's think positively, thank those that can assist the new company (like GENISES), and wait for a new, and brighter dawn! I wish Tim well, may he infect new and existing clients, with a reborn enthusiasm! Fortuna audax iuvat, (Fortune favours the Brave). Onwards and upwards! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
